P. Chambers

发表

No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene

D. Bishop, I. Dos Santos Silva, A. Swerdlow, 2005, Cancer Epidemiology Biomarkers & Prevention.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Susan Richman, Phil Quirke, Gary Middleton, 2013, The Lancet. Oncology.

Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor.

D. Neal, J. Mellon, P. Chambers, 1996, British Journal of Cancer.

Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

T. Hickish, S. Gwyther, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

M. D. James, R. Butler, P. Quirke, 2015, Journal of Clinical Pathology.

Quantitative assays of epidermal growth factor receptor in human breast cancer: Cut‐off points of clinical relevance

A. Harris, P. Chambers, J. Sainsbury, 1988, International journal of cancer.

Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA

S. Cross, A. Cox, I. Brock, 2016, PloS one.

Differential CpG DNA methylation in peripheral naïve CD4+ T-cells in early rheumatoid arthritis patients

P. Emery, F. Ponchel, A. Burska, 2020, Clinical Epigenetics.

Clinicopathologic Features of V600E and V600K Melanoma—Letter

M. Harland, J. Newton-Bishop, F. Elliott, 2012, Clinical Cancer Research.

Comprehensive Analysis of CDKN 2 A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency , a High Frequency of Homozygous Co-deletion and Associationswith Clinical Phenotype

P. Harnden, P. Chambers, A. Knowles, 2005 .

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

J. Barrett, P. Quirke, F. Elliott, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients

P. Karran, J. McGregor, C. Proby, 2008, British Journal of Cancer.

Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck

K. Harrington, P. Workman, C. Nutting, 2009, The Journal of pathology.

A mutation hotspot at the p14ARF splice site

J. A. Bishop, D. Bishop, M. Tucker, 2005, Oncogene.

Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer

G. Jenkins, P. Chambers, J. Beynon, 2017, World Journal of Surgery.

EGFR mutations in exons 18-21 in sporadic breast cancer.

S. Fox, A. Harris, D. Generali, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype

M. Knowles, C. Johnston, P. Harnden, 2005, Clinical Cancer Research.

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

H Snowden, M. Knowles, F. Platt, 2010, Oncogene.

Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway

M. Knowles, C. Hurst, E J Chapman, 2006, Oncogene.

Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase‐immortalized urothelial cells (TERT‐NHUC)

M. Knowles, C. Hurst, F. Platt, 2009, Genes, chromosomes & cancer.

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

D. Kerr, R. Gray, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis

Valerie Speirs, Lucy F. Stead, Lucy F Stead, 2015, PloS one.

Ischemia- reperfusion Injury and Its Influence on the Epigenetic Modification of the Donor Kidney Genome

M. D. Parker, P. Chambers, J. Lodge, 2008, Transplantation.

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

P. Quirke, S. Richman, C. Daly, 2011, Analytical cellular pathology.

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

J. Barrett, D. Kerr, R. Gray, 2016, The Journal of pathology.

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

P. Quirke, J. Worlding, S. Beare, 2017, British Journal of Cancer.

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study

Y. Miyagi, H. Grabsch, T. Yoshikawa, 2013, British Journal of Cancer.

Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.

B. Angus, A. Harris, P. Chambers, 1988, British Journal of Cancer.

In vitro functional effects of XPC gene rare variants from bladder cancer patients

A. Kiltie, M. Churchman, T. Bishop, 2011, Carcinogenesis.

KRAS and BRAF mutations in Nigerian colorectal cancers.

H. Grabsch, P. Quirke, F. Abdulkareem, 2012, West African journal of medicine.

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study

H. Grabsch, T. Yoshikawa, G. Meijer, 2014, British Journal of Cancer.

Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics

Lucy F. Stead, G. Taylor, P. Quirke, 2013, Human mutation.

validation of

M. D. James, R. Butler, B. Jasani, 2023 .

KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial

R. Gray, B. Warren, P. Quirke, 2012 .

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

M. D. James, R. Butler, P. Quirke, 2015, Journal of Clinical Pathology.